Literature DB >> 10639643

Deep Venous Thrombosis: Early Discharge Strategies and Outpatient Management.

.   

Abstract

Conventional management of acute deep venous thrombosis (DVT) consists of initiating continuous infusion intravenous unfractionated heparin (UFH) for 5 days in the hospital as well as warfarin. Low-molecular-weight heparins (LMWHs) appear to confer similar protection against recurrent DVT compared with UFH but exhibit prolonged bioavailability, increased ease of dosing, and fewer side effects. The advent of LMWH has resulted in increased numbers of patients undergoing initial management of acute DVT with only several days of hospitalization. While 3-month follow-up studies with LMWH demonstrate similar efficacy and safety to UFH, longer term experience with these new agents is necessary to determine their optimal use and safety. We suggest a system for triage in the initial management of DVT patients for: (1) complete outpatient management with LMWH, or (2) short-term hospitalization for initiation of LMWH, or (3) 5-day hospitalization for treatment with UFH. A review of DVT management with LMWH and algorithms for each of these pathways are provided.

Entities:  

Year:  1997        PMID: 10639643     DOI: 10.1023/a:1008849416842

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

3.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

4.  Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.

Authors:  D P Brandjes; H R Büller; H Heijboer; M V Huisman; M de Rijk; H Jagt; J W ten Cate
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

5.  The long-term clinical course of acute deep venous thrombosis.

Authors:  P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

6.  Heparin and the in-hospital management of deep venous thrombosis: cost considerations.

Authors:  T W Rooke; P J Osmundson
Journal:  Mayo Clin Proc       Date:  1986-03       Impact factor: 7.616

7.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Authors:  M Levine; M Gent; J Hirsh; J Leclerc; D Anderson; J Weitz; J Ginsberg; A G Turpie; C Demers; M Kovacs
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

8.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

9.  Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.

Authors:  R Hull; T Delmore; C Carter; J Hirsh; E Genton; M Gent; G Turpie; D McLaughlin
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

10.  Inhibition of hypoxic pulmonary hypertension by heparins of differing in vitro antiproliferative potency.

Authors:  B T Thompson; C R Spence; S P Janssens; P M Joseph; C A Hales
Journal:  Am J Respir Crit Care Med       Date:  1994-06       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.